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CLINICAL TRIALS AND OBSERVATIONS
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Key Points
• AML induction with liposomal
daunorubicin (80 mg/m2
per day for 3 days) shows
antileukemic activity
comparable to idarubicin
(12 mg/m2 per day for 3 days).
• Liposomal daunorubicin
promises to be more active
in the t(8;21) subgroup and
causes less treatment-related
toxicity.
Outcomes of patients with acute myeloid leukemia (AML) improve significantly
by intensification of induction. To further intensify anthracycline dosage without
increasing cardiotoxicity, we compared potentially less cardiotoxic liposomal daunorubicin
(L-DNR) to idarubicin at a higher-than-equivalent dose (80 vs 12 mg/m2 per day for 3
days) during induction. In the multicenter therapy-optimization trial AML-BFM 2004,
521 of 611 pediatric patients (85%) were randomly assigned to L-DNR or idarubicin
induction. Five-year results in both treatment arms were similar (overall survival 76%6 3%
[L-DNR] vs 75% 6 3% [idarubicin], Plogrank 5 .65; event-free survival [EFS] 59%6 3%
vs 53% 6 3%, Plogrank 5 .25; cumulative incidence of relapse 29% 6 3% vs 31% 6 3%,
P(Gray) 5 .75), as were EFS results for standard (72% 6 5% vs 68% 6 5%, Plogrank 5 .47)
and high-risk (51% 6 4% vs 46% 6 4%, Plogrank 5 .45) patients. L-DNR resulted in
significantly better probability of EFS in patients with t(8;21). Overall, treatment-related
mortality was lower with L-DNR than idarubicin (2/257 vs 10/264 patients, P 5 .04).
Grade 3/4 cardiotoxicity was rare after induction (4 L-DNR vs 5 idarubicin). Only 1 L-DNR
and 3 idarubicin patients presented with subclinical or mild cardiomyopathy during
follow-up. In conclusion, at the given dose, L-DNR has overall antileukemic activity comparable to idarubicin, promises to be more
active in subgroups, and causes less treatment-related mortality. This trial was registered at www.clinicaltrials.gov as #NCT00111345.
(Blood. 2013;122(1):37-43)
Introduction
Intensiﬁcation of induction treatment has had the greatest impact
on improving the rate of ﬁrst remission and overall survival (OS) in
adult and pediatric acute myeloid leukemia (AML).1,2 Recently,
Lo¨wenberg et al3 reported the effect of increasing anthracycline doses
during induction in adults. However, dose-related anthracycline
toxicity, especially acute and late cardiotoxicity, might limit further
treatment intensiﬁcation, particularly in children.4-6
Standard AML induction therapy in children and adults comprises
3 days of anthracycline administration [eg, daunorubicin>60 mg/m2,
idarubicin 10-12 mg/m2, or the anthracenedione mitoxantrone
10-12 mg/m2] and 7210 days of cytarabine (100-200 mg/m2).
With these regimens, 80%-90% of children and adolescents
achieve complete remission (CR).7
In children, the risk of anthracycline cardiotoxicity is higher than
in adults, owing to the developing heart muscle, and there are limits
to increasing pediatric anthracycline doses during induction or total
cumulative doses.6 According to animal testing and experiences in
ﬁrst human clinical studies, a liposomal formulation of daunorubicin
(L-DNR) offers the possibility to increase single and cumulative
dosages of anthracyclines without increasing cardiotoxicity.8-12
Here we report on the randomized introduction of L-DNR
during induction in the Multicenter Therapy-Optimization Trial
AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias
in Children and Adolescents at a dose of 80 mg/m2 per day for
3 days, which is higher than the dose of idarubicin that is pro-
vided in the control arm (standard 12 mg/m2 per day for 3 days,
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corresponding to 60 mg/m2 per day for 3 days L-DNR,
equivalent dose conversion of 1:5),13,14 both in combination
with cytarabine and etoposide. A dose equivalent of 1:1 was assumed
for daunorubicin vs L-DNR, because the active substances are
chemically identical, and only the pharmacokinetics are differ-
ent. The aim was (1) to improve outcome by increasing anthracycline
dosage during induction; and (2) to evaluate treatment-related
mortality (TRM) and toxicity, including acute and long-term
cardiotoxicity.
Patients and methods
Patients
Between March 2004 and April 2010, 611 AML patients ,18 years of age
were enrolled in the population-based study AML-BFM 2004. Of these,
521 were randomized (257 L-DNR induction vs 264 idarubicin induction)
and 90 (15%) were not randomized (for details, see Figure 1 CONSORT
[Consolidated Standards of Reporting Trials] diagram). Patient outcome
was analyzed as randomized on an intent-to-treat basis, and toxicities were
analyzed as treated. Patients with acute promyelocytic leukemia (APL) were
included in the protocol, because the chemotherapy regimen was similar to
that of standard-risk (SR) AML patients (except for additional all-trans-
retinoic acid courses). Outcome results with and without APL patients were
calculated. Patients with Down syndrome, to whom a reduced anthracycline
dosage is given a priori, were intentionally excluded from this analysis.
The AML-BFM 2004 study was performed in Germany, Austria,
Switzerland, and the Czech Republic. The study was approved by the
national ethics committees and institutional review boards in each country.
Written informed consent from patients, parents, or guardians was obtained
at study entry in accordance with the Declaration of Helsinki. Central review
of bone marrow morphology and cytogenetics was performed. Compre-
hensive cytogenetic data from 485 of the 521 patients (93%) were available.
Cytogenetic analysis was performed as previously described.15 Further,
routine testing for internal tandem duplications of FLT3 (FLT3-ITD) was
done at initial diagnosis, as stratiﬁcation to the high-risk (HR) group was
based on positivity for FLT3-ITD, among other criteria.
Treatment plan
The main study objective of AML-BFM 2004 was the improvement of
prognosis by intensiﬁcation of chemotherapy without increasing toxicity by
(1) randomized introduction of L-DNR (80 mg/m2 per day for 3 days) in a
dose higher than the assumed equivalent dose of idarubicin (12 mg/m2 per
day for 3 days) during induction, each combined with cytarabine and
Figure 1. CONSORT diagram of AML-BFM 2004
showing the flow of participants from enrollment
to randomization, therapy, follow-up, and analysis.
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etoposide; and (2) randomized introduction of 2-chloro-2-deoxyadenosine
(6 mg/m2 per day for 2 days) as intensiﬁcation during the cytarabine/
idarubicin consolidation for HR patients (Figure 2). Apart from that, the
treatment schedule of AML-BFM 2004 was for the most part similar to the
AML-BFM 98 protocol.16,17 An exception was the second induction with
HAM, which was administered generally to all patients in the AML-BFM
98 trial, but in AML-BFM 2004 to HR patients only. Two additional short
cycles with 0.5 g/m2 cytarabine and HDAC (1 g/m2) plus anthracyclines were
given after ﬁrst induction (SR patients) or second induction (HR patients),
followed by intensiﬁcation with HDAC/etoposide and maintenance. The
indication for allogeneic hematopoietic stem cell transplantation (HSCT) from
sibling donors in CR1 was restricted to HR patients17 and, since 2006,
recommended only for HR patients with bone marrow blasts .5% after
second induction.18 Intrathecal cytarabine was given 11-12 times according
to age-dependent dosage regimens. Randomized cranial irradiation (12 vs
18 Gy), which was performed over 2 study periods, was stopped in May
2009.17
Definitions and statistics
Patients were stratiﬁed into either a SR or HR group. SR was deﬁned as
FAB (French-American-British) M1/M2 with Auer rods; FAB M4eo or
favorable cytogenetics [t(8;21)/AML1-ETO or inv(16) or t(16;16) and/or
CBFB/MYH1)]; bone marrow blasts,5% on day 15; or FABM3 (all patients).
HR was deﬁned as all others. SR patients were reclassiﬁed to the HR group if
FLT3-ITD positive.
Early death (ED) was deﬁned as death before or within the ﬁrst 6 weeks
(42 days) of treatment and further subdivided into (1) ED before or within
the ﬁrst 15 days of therapy, which mainly reﬂects lethal events due to
hyperleukocytosis/leukostasis and bleeding; and (2) ED within days 16-42
of treatment, which mainly reﬂects deaths due to infectious complications
during aplasia after induction.19 CR was deﬁned according to the CALGB
(Cancer and Leukemia Group B) criteria20 achieved at the end of intensiﬁcation
treatment. OS was calculated from date of diagnosis to death of any cause,
and event-free survival (EFS) from diagnosis until ﬁrst event (failure to
achieve remission [calculated as an event at t 5 0], relapse, secondary
malignancy, or death by any cause) or last follow-up. Probabilities of
survival were estimated using the Kaplan–Meier method with standard
errors according to Greenwood21 and compared with the log-rank test.
Cumulative incidence functions of relapse, secondary malignancy, and
incidence of cardiac toxicity were constructed by the method of Kalbﬂeisch
and Prentice.21 Competing events for cardiac toxicity were HSCT in CR1,
relapse, and death. Functions were compared by Gray test. Toxicity was
assessed according to the National Cancer Institute common toxicity
criteria (CTC) version 2.0 (http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/docs/ctcv20_4-30-992.pdf). Cardiotoxicity of grade
1/2 was called subclinical, and grade 3/4, clinical. During follow-up, patients
had to be evaluated once a year for symptoms and echocardiographic
changes suggestive of cardiac toxicity.
Univariate analysis was conducted by Wilcoxon test for quantitative
variables and Fisher exact test or x2 statistics for qualitative variables.
Computations were performed using SAS (Statistical Analysis System,
version 9.1; SAS Institute, Cary, NC). Date of evaluation was March 15,
2012, and median follow-up time was 5.0 (range 0.5-8.5) years.
The study was designed to have a power of 80% to detect a 13% dif-
ference in 5-year EFS probability (pEFS, baseline 50%) by including 245
patients per group. Two interim analyses were planned after 3 and 5
years. Sample size calculation was done according to Freedman22 and
corrected for interim analysis using the R procedure gsDesign.
Results
Patient characteristics
Table 1 shows characteristics of the cohorts randomized in the
L-DNR or idarubicin arm. Patient characteristics were comparable
in the randomized groups and also in the corresponding groups as
treated (data not shown).
Overall results
Five-year pOS and pEFS values in all patients (n 5 611) were
74%6 2% and 55%6 2%, respectively (Figure 3). Survival rates
were improved compared with the previous study, AML-BFM 98
(n 5 473, 65% 6 2%, Plogrank 5 .001), whereas pEFS results were
in the same range (51% 6 2%, Plogrank 5 .24, results updated).
16
Results for the 217 SR patients were favorable: pOS 89% 6 2%,
pEFS 71% 6 3%, and results for the 394 HR patients were
suitable, pOS 65% 6 3%, pEFS 46% 6 3%. In comparing patients
who were randomized (n 5 516) and nonrandomized (n 5 90)
(patients with ED before day 15 excluded), pEFS results were
similar (56% 6 2% vs 54% 6 6%, Plogrank 5 .88).
Randomization of L-DNR vs idarubicin
Results for L-DNR (n 5 257) vs idarubicin (n 5 264) patients were
similar: 5-year pOS 76% 6 3% vs 75% 6 3%, Plogrank 5 .65, pEFS
59%6 3% vs 53%6 3%, Plogrank5 .25 (Figure 4) and cumulative
incidence of relapse at 5 years 29%6 3% vs 31%6 3%, PGray5 .79
(Table 2). Results in SR or HR patients were also similar (5-year
pEFS SR 72%6 5% vs 68%6 5%, Plogrank5 .47; HR 51%6 4%
vs 46%6 4%, Plogrank5 .45). TRM was lower in the L-DNR group
than the idarubicin group; for details see “Acute toxicity” below, and
Table 2. Results according to treatment as randomized were similar
to those as given (data not shown). When APL patients were
excluded, results were similar to those of the total group (5-year
pOS 74%6 3% vs 74%6 3%, Plogrank5 .75, pEFS 56%6 3% vs
51% 6 3%, Plogrank 5 .33). There was 1 ED from intracerebral
bleeding in an APL patient.
Figure 2. Treatment schedule of AML-BFM 2004
induction. First induction, AIE (cytarabine/idarubicin/
etoposide) or randomized (R1) with ADxE (cytarabine/
L-DNR/etoposide); second induction, (high-dose cytarabine
[3g/m2]/mitoxantrone) (HAM); consolidation, HAM or
randomized (R2) AI/2-CDA (cytarabine [0.5 g/m2]/
idarubicin/2-chloro-2-deoxyadenosine) vs AI (cytar-
abine [0.5 g/m2]/idarubicin); intensification: HAE (high-
dose cytarabine [3 g/m2]/etoposide), CNS-RT (central
nervous system [cranial] irradiation randomized [R3] to
12 or 18 Gy). APL patients received additional all-trans-
retinoic acid during all therapy courses. The cumula-
tive anthracycline dosages in SR and HR patients were,
with AIE induction, 350 and 450 mg/m2, respectively;
with ADxE, 410 and 510 mg/m2. IT, intrathecal.
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Cytogenetic subgroups
Results in 29 patients with t(8;21) and treated with L-DNR were
signiﬁcantly better than in those who received idarubicin (n 5 29):
pEFS 76% 6 8% vs 54% 6 9%, Plogrank 5 .04. This difference for
pEFS was not seen for the whole group of core-binding-factor
leukemias (Plogrank 5 .28), and there were no signiﬁcant differ-
ences after administration of either L-DNR or idarubicin in patients
with inv(16). No further differences were seen in the cohort analysis
of patients with t(15;17), normal karyotype, or MLL rearrangements
(data not shown).
Bone marrow blast count on days 15 and 28
Data of early response to induction treatment evaluated by analysis
of d 15 bone marrow showed a signiﬁcantly higher number of
patients with .5% blasts in the L-DNR arm (59/239 5 25% vs
35/235 5 15%, P 5 .008); however, the difference was not evident
in day 28 blast counts (Table 2).
Acute toxicity
Time to recovery of neutrophils to 500/mL after induction was
similar in both arms (L-DNR median 20.0 days, quartile 1 [Q1]-Q3
14-26 days, vs idarubicin median 21.0 days, Q1-Q3 12-27 days;
P 5 .73), as was time to recovery of platelets to 20 000/mL
(L-DNR median 9.0 days, Q1-Q3 2-17 days, vs idarubicin median
12.0 days, Q1-Q3 3-17 days; P 5 .16).
The rate of severe infections was slightly, but not signiﬁcantly,
lower with L-DNR (PFisher 5 .21) (Table 3). After induction, trans-
aminases were more often elevated in L-DNR patients than in those
treated with idarubicin; however, this was transient and not of clinical
importance. Skin toxicity was low in both groups. Four L-DNR
patients suffered from either arrhythmia (n 5 1) or reduced cardiac
function grade 3/4 (n5 3), which occurred during sepsis in 2 patients.
In 5 idarubicin patients, cardiac function was reduced, and 3 of
those also had arrhythmia. Because 3 of these patients suffered
from additional severe infections, these cases cannot be considered
as cardiotoxicity caused solely by anthracyclines. One of these
patients died on d 3 of induction with life-threatening bleeding and
acute respiratory distress syndrome (ARDS); another 2 patients died
on days 17 and 22, respectively, from severe infections. The other
2 patients presented with grade 3 cardiotoxicity after induction,
one of them with concurrent pneumonia. There was no grade 1-4
cardiotoxicity in the patients of the L-DNR and idarubicin groups
after the HAM course.
ED and TRM in patients treated with L-DNR and idarubicin
are illustrated in Table 2. ED before day 15 was mostly due to
cerebral bleeding, related to initial hyperleukocytosis and co-
agulation disturbance or to ARDS. TRM following induction
treatment occurred in 2 patients due to fungal and bacterial
infections after L-DNR induction and in 5 patients of the idarubicin
group (severe infections/septicemia/ARDS). Another 5 patients of
the idarubicin group died after HAM or the subsequent 3 in-
tensive courses due to bacterial and fungal septicemia, abscess, or
thromboembolism. Considering also TRM during intensiﬁca-
tion, the TRM rate of the L-DNR group was signiﬁcantly
lower compared with the idarubicin group: 2 of 257 vs 10 of
264, P 5 .04.
Table 1. Baseline data for patients randomized to L-DNR vs idarubicin
L-DNR Idarubicin P*
n 257 264
Age, y, median (Q1-Q3) 9.8 (2.4-14.5) 8.3 (2.2-14.1) .28
Leukocytes, 3103/mL,
median (range)
15 050 (4785-61 700) 16 300 (4550-56 350) .88
Gender .66
Male 135 (52) 133 (50)
Female 122 (48) 131 (50)
CNS involvement, n/total
n (%)
22/252 (9) 39/259 (15) .03†
Extramedullary organ
involvement
67 (26) 56 (21) .19
Cytogenetic data available,
n/total n (%)
239/257 (93) 247/264 (94)
Cytogenetic data .11
t(8;21) 29 (12) 29 (12)
t(15;17) 24 (10) 14 (6)
inv(16) 24 (10) 20 (8)
Normal 41 (17) 63 (26)
Other 121 (51) 121 (49)
Risk groups .68
SR 94 (37) 92 (35)
HR 163 (63) 172 (65)
Data are n (%) unless stated otherwise. Q, quartile; CNS, central nervous system.
*By x2 test.
†No differences were found in OS, EFS, or cumulative incidence of relapse in
CNS-positive or -negative patients.
Figure 3. Estimated probability of 5-year OS and EFS in all patients from AML-
BFM 2004. SE, standard error.
Figure 4. Estimated 5-year pEFS in patients randomized to L-DNR (ADxE) vs
idarubicin (AIE). SE, standard error.
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Late toxicity
Secondary malignancies. One patient in the L-DNR arm devel-
oped a secondary malignancy (acute lymphoblastic leukemia), as
did 3 patients in the idarubicin arm (1 acute lymphoblastic leukemia
and 2 myelodysplastic syndrome).
Late cardiotoxicity. Five-year cumulative incidence of late
and persistent (subclinical and clinical) cardiotoxicity in CR1 was
assessed in median after 5 (0.9–8.5) years, excluding those with
transient cardiac dysfunction (ie, CTC grade 1 recorded at only
1 time point) and those with either HSCT in CR1 or relapse. The
incidence values were 0.7% (n 5 1) in the L-DNR group and 1.8%
(n 5 3) in the idarubicin group (Table 4). In detail, the sole patient
in the L-DNR cohort was a 3-year-old girl who suffered from mild
therapeutically compensated clinical cardiomyopathy (grade 3).
Treatment with angiotensin-converting enzyme (ACE) inhibitors
was stopped 7.6 years after diagnosis.
In patients treated with idarubicin, 1 patient suffered from
subclinical cardiomyopathy after 2.3 and 4.0 years from diagnosis,
presenting with reduced shortening fraction (SF) CTC grade 1. Later
controls were without pathological ﬁndings. Another case with sub-
clinical cardiotoxicity remained unclear, as follow-ups were refused
(see Table 4). Two girls showed mild therapeutically compensated
clinical cardiomyopathy in CR1. One developed cardiac functional
impairment (CTC grade 3) during consolidation, suffered from
hypotension 1.5 years after diagnosis, and 6 months later from
arrhythmia with a reduced SF CTC grade 1. She recovered during
follow-up and remained without signs of cardiotoxicity 4.5 years
after diagnosis. The second girl showed reduced SF CTC grade 2
after induction and received no further idarubicin, but mitoxan-
trone. After 4 years of follow-up, she had mildly reduced SF CTC
at 2 occasions, and ACE inhibitor treatment was indicated. In all
patients of both treatment groups with controls, SF improved during
times of follow-up.
Multivariate analysis
Cox regression analysis was performed including the following
variables: treatment arm, cytogenetic risk group [SR: t(8;21),
inv(16), t(15;17) vs other], MLL rearrangements, age (, vs >10
years), leukocytes (, vs >20 000 3 103/mL), and an interaction
term between therapy (randomized treatment with L-DNR) and
t(8;21). Only unfavorable cytogenetics was an independent risk
factor (hazard risk ratio 5 2.64, 95% conﬁdence interval 1.72-4.04,
Px2 5 .000; the interaction between treatment and t(8;21) was not
signiﬁcant (Px2 5 .97).
Discussion
Dose intensity during induction, along with the cumulative dose of
anthracyclines, plays a major role in the treatment of AML.2,3,13
Based on several randomized trials comparing anthracyclines in AML
therapy, idarubicin appeared to be very efﬁcacious.13,14 However,
children are more susceptible to anthracycline cardiotoxicity than
adults because of ongoing heart muscle growth. It is thus of high
importance to minimize cardiotoxicity in anthracycline-based
regimens.
L-DNR is a liposomally entrapped daunorubicin with a more
favorable pharmacology than free daunorubicin.23 Low accumu-
lation of L-DNR in the heart has been proven in animals, and
minimal cardiotoxicity despite signiﬁcant antileukemic activity
was found in a mouse model.8,9 In 277 AIDS patients with Kaposi
sarcoma, no cardiotoxicity of L-DNR was seen, after cumulative
doses of up to 1700 mg/m2.10 Hence, liposomal anthracyclines are
believed to cause less cardiotoxicity at higher cumulative doses
than conventional anthracyclines.10,11,24-26
Based on these data, we assumed that higher doses of this
liposomal anthracycline could be administered safely. Notably,
we found previously that idarubicin was somewhat superior to
conventional DNR in induction at a conversion factor of 1:5,14 but
observations of the Children’s Cancer Group27 made us doubt that
the idarubicin dose could be further increased. Thus, in AML-BFM
2004, we randomized L-DNR at a dose of 80 mg/m2 per day for
3 days vs standard induction with idarubicin at 12 mg/m2 per day for
3 days (corresponding to L-DNR 60 mg/m2/ per day for 3 days).
Overall, we found similar response rates after induction and com-
parable long-term outcome. Hence, this surmised mild dose increase
did not translate into largely different efﬁcacy. Notably, our study
was underpowered to discriminate small differences: to show a
Table 2. Results of randomized patients
L-DNR Idarubicin P*
n 257 264
ED (before d 42) 5 (2) 7 (3) .59
ED (before d 15) related to initial
complications
3 2
ED/TRM (d 15 or later) after induction 2 5
Death in CCR (TRM) 1 (0.4) 6 (3) .02
TRM during intensification courses 0 5
TRM after HSCT in first CR 1 1
Total ED/TRM following induction
treatment
2 10 .04
Blasts .5% at d 15, n/total n (%) 59/239 (25) 35/235 (15) .01
Blasts .5% at d 28, n/total n (%) 46/202 (23) 37/206 (18) .27
Nonresponders 24 (9) 25 (10) .97
CR achieved 228 (89) 232 (88) .79
Relapse, cumulative incidence,
n (% 6 SE)
74 (29 6 3) 79 (31 6 3) .79
Secondary malignancies, cumulative
incidence, n (% 6 SE)
1 (1 6 1) 3 (1 6 1) .29
5-y pOS, % 6 SE 76 (3) 75 (3) .65
5-y pEFS, % 6 SE 59 (3) 53 (3) .25
Data are n or n (%) unless stated otherwise. CCR, continuous complete remission.
*By Gray test (except for 5-year pOS and pEFS, which are by log rank test).
Table 3. Toxicity (CTC score III/IV) after induction in patients treated
with L-DNR and idarubicin
L-DNR Idarubicin P
General condition 86/223 (39) 116/260 (45) .18
SGOT, SGPT 32/225 (14) 20/258 (8) .02
Arrhythmia 1/215 (0.5) 3/252 (1.2) .40
Cardiac function (congestive heart failure) 3/183 (1.6) 5/221 (2.3)* .65
Echocardiography 0/186 (0) 0/214 (0) —
Cardiac total 4/183 (2.1)* 5/214 (2.3)† 1.0
Central neurotoxicity 4/226 (1.8) 7/261 (2.7) .50
Infection 70/226 (31.0) 95/261 (36.4) .21
Pulmonary toxicity 33/204 (16) 35/248 (14) .54
Mucositis 58/225 (26) 64/259 (25) .79
Skin toxicity 8/223 (3.6) 7/256 (2.7) .58
Data are n/total n (%). SGOT, serum glutamic oxaloacetic transaminase; SGPT,
serum glutamic pyruvic transaminase.
*One patient died associated with sepsis.
†Three patients died associated with ARDS and sepsis (see “Acute toxicity”).
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pEFS improvement from 53% to 59% with 80% power, a 5 5%
2-sided, 1050 patients per group would have been needed. However,
our results in subgroups of patients and TRM show that L-DNR still
proved to be more effective and favorable.
For example, results by randomization were better for patients
with t(8;21) treated with L-DNR vs idarubicin. We suggest that this
might be due to the prolonged active plasma level of the liposomal
drug. We found it interesting to note that at day 15, a typical
response assessment time point,28,29 the idarubicin cohort showed
lower blast counts, whereas the 2 cohorts were no longer different
at d 28 before the second treatment course. Again, this could be
indicative of a prolonged effect of L-DNR compared with idarubicin,
and could be important for t(8;21) leukemias, which have a rel-
atively slow blast-cell clearance over time compared with other
cytogenetic subtypes. Notably, AML-BFM 2004 was designed with-
out HAM treatment in all SR patients, including those with t(8;21),
unlike AML-BFM 98. We have shown30 that second induction
with HAM is beneﬁcial for these patients. Nevertheless, we consider
now that the more favorable activity of L-DNR over idarubicin in
ﬁrst induction could compensate at least partly for the lack of HAM.
Overall, our 2004 results even improved over those of 1998. This
can mainly be seen by the high 5-year survival rates (74% 6 2% vs
65% 6 2%, Plogrank 5 .001).
Improved survival rates in pediatric AML, similar to those in
our study, have recently been reported by different treatment
groups from Japan, Europe, and the United States.31-34 In view
of these good results, which have been achieved with different but
always intensive strategies, it is even more important to reduce
acute and long-term toxicities to ensure the highest possible quality
of life. In our study, most acute toxicities, including hematological
and infectious complications, were in the expected range or tended
to be lower after treatment with L-DNR compared with idarubicin.
This is explicitly underpinned by a lower TRM rate in patients of
the L-DNR arm. Cardiotoxicity was low after induction in both
arms, and during follow-up, only 1 L-DNR patient and 2 idarubicin
patients required treatment with ACE inhibitors. However, the
assessment of long-term anthracycline cardiotoxicity requires longer
follow-up.6 Results from the prior AML-BFM trials (mainly with
idarubicin treatment) showed a relatively low rate of early clinical
and subclinical cardiotoxicity, and the 11-year cumulative incidence
of late clinical cardiotoxicity was 2.5%.35 However, our current
data on acute and long-term cardiotoxicity, although preliminary,
clearly reveal that an induction dose of 3 3 (80 mg/m2 per day)
L-DNR does not increase cardiotoxicity. Cardioprotection with
dexrazoxane might be another option to reduce anthracycline
cardiotoxicity.36 However, the application of that drug in those
,18 years old is discouraged owing to the risk of secondary
malignancies.37
In summary, L-DNR proves to be an effective drug within a
multiagent approach for treating de novo AML in children and
adolescents in general, and has speciﬁc activity in patients with
t(8:21). This speciﬁc effectiveness of L-DNR was also found in
Relapsed AML 2001/01,38 suggesting that core-binding-factor AML
is much more sensitive to anthracyclines in general (or more speciﬁc
to L-DNR) than other subtypes of AML. L-DNR shows a favorable
overall proﬁle, as well as a favorable cardiac toxicity proﬁle, and
eventually allows an increased anthracycline dose without increasing
cardiotoxicity. The AML-BFM study group will therefore continue
to use L-DNR in their forthcoming de novo AML trial.
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Table 4. Late cardiotoxicity in patients treated with L-DNR and
idarubicin
L-DNR Idarubicin
n 170 185
CTC score I 9 10
After relapse/HSCT* 4 3
No relapse/no HSCT and CTC score I only
once*
5 6†
No relapse/no HSCT and CTC score I present
.6 mo
0 1
CTC score III/IV 2 3
After relapse/HSCT* 1‡ 1
No relapse/no SCT and CTC score III/IV present
.6 mo
1 2
Total: No relapse/no HSCT and CTC score I-IV
present .6 mo
1 3
There were no CTC II cardiotoxicities.
*Excluded for the calculation of induction-related cardiotoxicity.
†One patient refused follow-up.
‡Patient died 7 days after HSCT with sepsis and cardiac failure.
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